China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy ...Middle East

PR Newswire - News
China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy
STOCKHOLM, Dec. 30, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") partner Everest Medicines (HKEX 1952.HK) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has recommended Priority Review for the...

Hence then, the article about china cde nmpa recommends priority review for nefecon for the treatment of primary iga nephropathy was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA Nephropathy )

Apple Storegoogle play

Last updated :

Also on site :



Latest News